ALK-Abelló A/S - Asset Resilience Ratio

Latest as of September 2019: 0.98%

ALK-Abelló A/S (ALK-B) has an Asset Resilience Ratio of 0.98% as of September 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALK-Abelló A/S (ALK-B) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Dkr50.00 Million
≈ $7.82 Million USD Cash + Short-term Investments

Total Assets

Dkr5.09 Billion
≈ $796.52 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2007–2019)

This chart shows how ALK-Abelló A/S's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of ALK-Abelló A/S.

Liquid Assets Composition Over Time

This chart breaks down ALK-Abelló A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ALK-Abelló A/S (ALK-B) investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Dkr0.00 0%
Short-term Investments Dkr50.00 Million 0.98%
Total Liquid Assets Dkr50.00 Million 0.98%

Asset Resilience Insights

  • Limited Liquidity: ALK-Abelló A/S maintains only 0.98% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

ALK-Abelló A/S Industry Peers by Asset Resilience Ratio

Compare ALK-Abelló A/S's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
Biotechnology 1.69%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
3SBio Inc
F:83B
Biotechnology 10.64%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%

Annual Asset Resilience Ratio for ALK-Abelló A/S (2007–2019)

The table below shows the annual Asset Resilience Ratio data for ALK-Abelló A/S.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2019-12-31 -2.91% Dkr-160.00 Million
≈ $-25.03 Million
Dkr5.50 Billion
≈ $859.73 Million
-4.97pp
2018-12-31 2.06% Dkr100.00 Million
≈ $15.65 Million
Dkr4.87 Billion
≈ $761.16 Million
-9.02pp
2017-12-31 11.07% Dkr549.00 Million
≈ $85.90 Million
Dkr4.96 Billion
≈ $775.72 Million
-0.35pp
2016-12-31 11.42% Dkr548.00 Million
≈ $85.74 Million
Dkr4.80 Billion
≈ $750.84 Million
+1.26pp
2015-12-31 10.16% Dkr432.00 Million
≈ $67.59 Million
Dkr4.25 Billion
≈ $665.26 Million
+4.08pp
2014-12-31 6.08% Dkr208.00 Million
≈ $32.54 Million
Dkr3.42 Billion
≈ $534.93 Million
-9.09pp
2007-12-31 15.17% Dkr428.00 Million
≈ $66.96 Million
Dkr2.82 Billion
≈ $441.37 Million
--
pp = percentage points

About ALK-Abelló A/S

CO:ALK-B Denmark Biotechnology
Market Cap
$6.15 Billion
Dkr39.29 Billion DKK
Market Cap Rank
#3136 Global
#20 in Denmark
Share Price
Dkr195.20
Change (1 day)
-0.36%
52-Week Range
Dkr195.20 - Dkr270.40
All Time High
Dkr270.40
About

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more